These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 34864936)

  • 1. Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections.
    Tamma PD; Aitken SL; Bonomo RA; Mathers AJ; van Duin D; Clancy CJ
    Clin Infect Dis; 2022 Jul; 74(12):2089-2114. PubMed ID: 34864936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections.
    Tamma PD; Aitken SL; Bonomo RA; Mathers AJ; van Duin D; Clancy CJ
    Clin Infect Dis; 2023 Jul; ():. PubMed ID: 37463564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections.
    Tamma PD; Heil EL; Justo JA; Mathers AJ; Satlin MJ; Bonomo RA
    Clin Infect Dis; 2024 Aug; ():. PubMed ID: 39108079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).
    Tamma PD; Aitken SL; Bonomo RA; Mathers AJ; van Duin D; Clancy CJ
    Clin Infect Dis; 2022 Aug; 75(2):187-212. PubMed ID: 35439291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).
    Tamma PD; Aitken SL; Bonomo RA; Mathers AJ; van Duin D; Clancy CJ
    Clin Infect Dis; 2021 Apr; 72(7):e169-e183. PubMed ID: 33106864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).
    Tamma PD; Aitken SL; Bonomo RA; Mathers AJ; van Duin D; Clancy CJ
    Clin Infect Dis; 2021 Apr; 72(7):1109-1116. PubMed ID: 33830222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: a systematic review and meta-analysis.
    Karakonstantis S; Rousaki M; Vassilopoulou L; Kritsotakis EI
    Clin Microbiol Infect; 2024 Feb; 30(2):178-188. PubMed ID: 37666449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment guidelines for multidrug-resistant Gram-negative microorganisms.
    Cantón R; Ruiz-Garbajosa P
    Rev Esp Quimioter; 2023 Nov; 36 Suppl 1(Suppl 1):46-51. PubMed ID: 37997871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
    Delgado-Valverde M; Conejo MDC; Serrano L; Fernández-Cuenca F; Pascual Á
    J Antimicrob Chemother; 2020 Jul; 75(7):1840-1849. PubMed ID: 32277821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bulgecin A as a β-lactam enhancer for carbapenem-resistant
    Skalweit MJ; Li M
    Drug Des Devel Ther; 2016; 10():3013-3020. PubMed ID: 27703329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibiotic-resistant gram-negative bacterial infections in patients with cancer.
    Perez F; Adachi J; Bonomo RA
    Clin Infect Dis; 2014 Nov; 59 Suppl 5(Suppl 5):S335-9. PubMed ID: 25352627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ESCMID/EUCIC clinical practice guidelines on perioperative antibiotic prophylaxis in patients colonized by multidrug-resistant Gram-negative bacteria before surgery.
    Righi E; Mutters NT; Guirao X; Del Toro MD; Eckmann C; Friedrich AW; Giannella M; Kluytmans J; Presterl E; Christaki E; Cross ELA; Visentin A; Sganga G; Tsioutis C; Tacconelli E
    Clin Microbiol Infect; 2023 Apr; 29(4):463-479. PubMed ID: 36566836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High burden of ESBL and carbapenemase-producing gram-negative bacteria in bloodstream infection patients at a tertiary care hospital in Addis Ababa, Ethiopia.
    Beshah D; Desta AF; Woldemichael GB; Belachew EB; Derese SG; Zelelie TZ; Desalegn Z; Tessema TS; Gebreselasie S; Abebe T
    PLoS One; 2023; 18(6):e0287453. PubMed ID: 37368908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of multidrug-resistant Gram-negative infections in children.
    Hsu AJ; Tamma PD
    Clin Infect Dis; 2014 May; 58(10):1439-48. PubMed ID: 24501388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Highly Resistant Gram-Negative Infections in the Intensive Care Unit in the Era of Novel Antibiotics.
    Clancy CJ; Nguyen MH
    Infect Dis Clin North Am; 2022 Dec; 36(4):791-823. PubMed ID: 36328637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is Ceftazidime/Avibactam an Option for Serious Infections Due to Extended-Spectrum-β-Lactamase- and AmpC-Producing
    Isler B; Ezure Y; Romero JLG; Harris P; Stewart AG; Paterson DL
    Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33046493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The interface between COVID-19 and bacterial healthcare-associated infections.
    O'Toole RF
    Clin Microbiol Infect; 2021 Dec; 27(12):1772-1776. PubMed ID: 34111586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carbapenem use in extended-spectrum cephalosporin-resistant Enterobacterales infections in US hospitals and influence of IDSA guidance: a retrospective cohort study.
    Walker MK; Diao G; Warner S; Babiker A; Neupane M; Strich JR; Yek C; Kadri SS;
    Lancet Infect Dis; 2024 Aug; 24(8):856-867. PubMed ID: 38679036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accuracy of American Thoracic Society/Infectious Diseases Society of America criteria in predicting infection or colonization with multidrug-resistant bacteria at intensive-care unit admission.
    Nseir S; Grailles G; Soury-Lavergne A; Minacori F; Alves I; Durocher A
    Clin Microbiol Infect; 2010 Jul; 16(7):902-8. PubMed ID: 19694760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.